Mergers & AcquisitionsMedium•28 September 2026•
1 min read
Webster Equity Partners to Acquire Lifecore Biomedical for $6.28 Per Share
Key Facts
1Lifecore stockholders will receive $6.28 per share in cash, representing a 49.5% premium.
2The deal includes Contingent Value Rights (CVRs) for up to $160 million in aggregate cash payments based on performance.
Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners in an all-cash transaction. According to a GlobeNewswire report, stockholders will receive $6.28 per share in cash, representing a 49.5% premium. The deal also includes Contingent Value Rights (CVRs) for up to $160 million in aggregate cash payments based on performance milestones.
LFCR closed at $4.2 on September 25, 2026, prior to the announcement of the acquisition intended to support the company's growth objectives. The transaction provides a significant cash premium to the current stock price alongside potential future payments linked to performance outcomes.